| Comprehensive genomic profiles of small cell lung cancer J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ... Nature 524 (7563), 47-53, 2015 | 2017 | 2015 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1473 | 2012 |
| A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal G Rindi, DS Klimstra, B Abedi-Ardekani, SL Asa, FT Bosman, E Brambilla, ... Modern Pathology 31 (12), 1770-1786, 2018 | 985 | 2018 |
| Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 K Ohashi, LV Sequist, ME Arcila, T Moran, J Chmielecki, YL Lin, Y Pan, ... Proceedings of the National Academy of Sciences 109 (31), E2127-E2133, 2012 | 510 | 2012 |
| Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids L Fernandez-Cuesta, M Peifer, X Lu, R Sun, L Ozretić, D Seidel, T Zander, ... Nature communications 5 (1), 3518, 2014 | 293 | 2014 |
| Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors J George, V Walter, M Peifer, LB Alexandrov, D Seidel, F Leenders, ... Nature communications 9 (1), 1048, 2018 | 292 | 2018 |
| CD74–NRG1 Fusions in Lung Adenocarcinoma L Fernandez-Cuesta, D Plenker, H Osada, R Sun, R Menon, F Leenders, ... Cancer discovery 4 (4), 415-422, 2014 | 280 | 2014 |
| Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors S Ortiz-Cuaran, M Scheffler, D Plenker, L Dahmen, AH Scheel, ... Clinical Cancer Research 22 (19), 4837-4847, 2016 | 258 | 2016 |
| Identification of circulating tumor DNA for the early detection of small-cell lung cancer L Fernandez-Cuesta, S Perdomo, PH Avogbe, N Leblay, TM Delhomme, ... EBioMedicine 10, 117-123, 2016 | 201 | 2016 |
| Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome JL Derks, N Leblay, E Thunnissen, RJ Van Suylen, M den Bakker, ... Clinical Cancer Research 24 (1), 33-42, 2018 | 185 | 2018 |
| EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach AG Nicholson, JL Sauter, AK Nowak, HL Kindler, RR Gill, M Remy-Jardin, ... Journal of Thoracic Oncology 15 (1), 29-49, 2020 | 152 | 2020 |
| Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids N Alcala, N Leblay, AAG Gabriel, L Mangiante, D Hervás, T Giffon, ... Nature communications 10 (1), 3407, 2019 | 148 | 2019 |
| New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management JL Derks, N Leblay, S Lantuejoul, AMC Dingemans, EJM Speel, ... Journal of Thoracic Oncology 13 (6), 752-766, 2018 | 125 | 2018 |
| Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer F Malchers, F Dietlein, J Schöttle, X Lu, L Nogova, K Albus, ... Cancer discovery 4 (2), 246-257, 2014 | 118 | 2014 |
| Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer L Fernandez-Cuesta, RK Thomas Clinical Cancer Research 21 (9), 1989-1994, 2015 | 90 | 2015 |
| Shared oncogenic pathways implicated in both virus-positive and UV-induced Merkel cell carcinomas M del Carmen Gonzalez-Vela, S Curiel-Olmo, S Derdak, S Beltran, ... Journal of Investigative Dermatology 137 (1), 197-206, 2017 | 89 | 2017 |
| p53 regulates the transcription of its Δ133p53 isoform through specific response elements contained within the TP53 P2 internal promoter V Marcel, V Vijayakumar, L Fernandez-Cuesta, H Hafsi, C Sagne, ... Oncogene 29 (18), 2691-2700, 2010 | 87 | 2010 |
| Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations S Lorenz, T Barøy, J Sun, T Nome, D Vodák, JC Bryne, AM Håkelien, ... Oncotarget 7 (5), 5273, 2016 | 85 | 2016 |
| BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas N Leblay, F Leprêtre, N Le Stang, A Gautier-Stein, L Villeneuve, S Isaac, ... Journal of Thoracic Oncology 12 (4), 724-733, 2017 | 83 | 2017 |
| Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant … L Fernández-Cuesta, C Oakman, P Falagan-Lotsch, E Quinaux, M Buyse, ... Breast Cancer Research 14, 1-13, 2012 | 72 | 2012 |
Matthieu FollInternational Agency for Research on Cancer (IARC/WHO)在 iarc.who.int 的电子邮件经过验证
